title: Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels.
abstract: Benign prostatic hyperplasia (BPH) is so common in elderly men that the development of adenomatous nodules in this organ can be seen as a normal age-dependent process. In this work, we used Northern blotting to compare the levels of androgen, estrogen, and insulin-like growth factor-I (IGF-I) receptor in young (age range, 23-33; n = 3), old normal (age range, 52-80; n = 3), and BPH-affected subjects (age range, 66-87; n = 15). We have also investigated in these groups the expression of genes coding for the two 5 alpha-reductases (types I and II), aromatase, IGF-I, and IGF-II. Our results show significantly increased levels of IGF mRNA in old healthy and BPH-affected subjects; the respective rises for IGF-I, IGF-II, and IGF-I receptor mRNAs were 3.0-, 2.9-, and 1.5-fold (BPH) and 2.7-, 2.4-, and 1.8-fold (old normal controls). For estrogen receptor, androgen receptor, and type I and II 5 alpha-reductase mRNAs, a marked but opposite effect was observed in adenomatous tissues only; the respective levels were 2.2-, 1.8-, 3.9-, and 1.7-fold lower than those in young adult subjects, whereas no significant differences were recorded between the two normal groups. Morphometric analysis of each tissue specimen confirmed the significantly lower epithelium/stroma ratio in adenomas compared to young or old healthy tissues. Together, these observations suggest that prostatic adenomas may result from at least two conjugate processes: one characterized by a drop in the mRNA levels of steroid hormone receptors, which might be associated with a lower epithelium/stroma ratio, and another characterized by normal aging phenomena, of which the increased production of IGFs and IGF-I receptor transcripts could be biochemical markers.
authors.affiliation: Laboratoire d'Endocrinologie, Université de Liege, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Bonnet
authors.forename: E
authors.initials: E
authors.lastname: Reiter
authors.forename: M
authors.initials: M
authors.lastname: Bruyninx
authors.forename: B
authors.initials: B
authors.lastname: Sente
authors.forename: D
authors.initials: D
authors.lastname: Dombrowicz
authors.forename: J
authors.initials: J
authors.lastname: de Leval
authors.forename: J
authors.initials: J
authors.lastname: Closset
authors.forename: G
authors.initials: G
authors.lastname: Hennen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D042944:Cholestenone 5 alpha-Reductase; D006801:Humans; D008297:Male; D008875:Middle Aged; D010088:Oxidoreductases / Q000235:genetics*; D011467:Prostate / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*; D011987:Receptors, Steroid / Q000235:genetics*; D012016:Reference Values; D013002:Somatomedins / Q000235:genetics
chemical_list: D012333:RNA, Messenger; D011987:Receptors, Steroid; D013002:Somatomedins; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase